Abstract:Non-classical congenital adrenal hyperplasia (NCCAH) is considered to be a common monogenic inherited disease, with an incidence range from 1:500 to 1:100 births worldwide. However, despite the high incidence, there is a low genotype-phenotype correlation, which explains why NCCAH diagnosis is usually delayed or even never carried out, since many patients remain asymptomatic or are misdiagnosed as suffering from other hyperandrogenic disorders. For affected adolescent and adult women, it is crucial to investigate any suspicion of NCCAH and determine a firm and accurate diagnosis. The Synacthen test is a prerequisite in the event of clinical suspicion, and molecular testing will establish the diagnosis. In most cases occurring under 8 years of age, the first symptom is premature pubarche. In some cases, due to advanced bone age and/or severe signs of hyperandrogenism, initiation of hydrocortisone treatment prepubertally may be considered. Our unifying theory of the hyperandrogenic signs system and its regulation by internal (hormones, enzymes, tissue sensitivity) and external (stress, insulin resistance, epigenetic, endocrine disruptors) factors is presented in an attempt to elucidate both the prominent genotype-phenotype heterogeneity of this disease and the resultant wide variation of clinical findings. Treatment should be initiated not only to address the main cause of the patient's visit but additionally to decrease abnormally elevated hormone concentrations. Goals of treatment include restoration of regular menstrual cyclicity, slowing the progression of hirsutism and acne, and improvement of fertility. Hydrocortisone supplementation, though not dexamethasone administration, could, as a general rule, be helpful, however, at minimum doses, and also for a short period of time and, most likely, not lifelong. On the other hand, in cases where severe hirsutism and/or acne are present, prescription of oral contraceptives and/or antiandrogens may be advisable. Furthermore, women with NCCAH commonly experience subfertility, therefore, there will be analysis of the appropriate approach for these patients, including during pregnancy, based mainly on genotype. Besides, we should keep in mind that since the same patient will have changing requirements through the years, the attending physician should undertake a tailor-made approach in order to cover her specific needs at different stages of life.

Molecular Physiopathology, Late Diagnoses, and Personalized Management

A3309 Clinical and Genetic Analysis of a Pedigree with Congenital Adrenal Hyperplasia (17Α-Hydroxylase /17,20-Lyase Deficiency) Literature

Cardiometabolic Aspects of Congenital Adrenal Hyperplasia

Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care

Prenatal and Pregnancy Management of Congenital Adrenal Hyperplasia

Endocrine, cardiac and neuropsychological aspects of adult congenital adrenal hyperplasia

Development in diagnosis and treatment of congenital adrenocortical hyperplasia

Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency - management in adults

Molecular Diagnosis of Two Families with Classic Congenital Adrenal Hyperplasia

Treatment for Congenital Adrenal Hyperplasia with 21-Hydroxylase Deficiency

Prenatal diagnosis and in utero treatment of congenital adrenal hyperplasia: An up‐to‐date comprehensive review

Late diagnosis of partial 3β-hydroxysteroid dehydrogenase type 2 deficiency - characterization of a new genetic variant

Current status and prospects of congenital adrenal hyperplasia: A bibliometric and visualization study

Congenital adrenal hyperplasia disorder due to 17 α-hydroxylase deficiency: a case report

Management of the Female With Non-classical Congenital Adrenal Hyperplasia (NCCAH): A Patient-Oriented Approach

Recent progress of 11β-hydroxylase deficiency

Progress in Molecular-Genetic Studies on Congenital Adrenal Hyperplasia Due to 11Β-Hydroxylase Deficiency

Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: is the risk real?

Landscape of congenital adrenal hyperplasia cases in adult endocrinology clinics of Türkiye-a nation-wide multicentre study

Clinical Features of Infants with Congenital Adrenal Hyperplasia